Sanofi Maps Out R&D Expectations For 2H 2021
Readouts In Cancer, COVID-19 And Pemphigus
Sanofi has transformed the productivity of its R&D pipeline over the past several years, and late-stage clinical data readouts are expected in the second half of this year for new anticancer drugs, a candidate pemphigus therapy and a COVID-19 vaccine.
